The UK’s medicines regulator has joined an international call to accelerate the replacement of animal testing across the full life cycle of medicines, in a move that could shape how drugs are developed, screened, and monitored in the years ahead. The Medicines and Healthcare products Regulatory Agency said the initiative is aimed at replacing animal testing at every stage, from early screening and non-clinical testing through to licensing and post-authorisation activities.
The announcement was made on October 1, 2026, when the MHRA joined global regulators in backing the long-term goal of replacing animal testing across medicine development. The agency said it has already taken steps in this direction earlier in 2026, including action in March to support the phase-out of animal testing.
What the MHRA says the move is designed to achieve
The regulator described the effort as part of a broader shift towards modern, more predictive approaches in medicines regulation. According to the MHRA, the ambition is to move away from animal use and towards methods that can support safer and more efficient development while maintaining standards for patient protection.
The agency said the new international position is intended to cover the full medicine lifecycle, which means the change is not limited to laboratory research alone. Instead, it extends to the regulatory steps that come after a medicine is first developed, including later-stage assessment and monitoring once a product is in use.
A wider regulatory direction
The MHRA’s position comes amid a wider programme of reform in UK health regulation. In recent months, the government has also backed the recommendations of the NHS doctors-led AI Commission, and the MHRA has highlighted work to modernise how it regulates emerging technologies. That broader context suggests the agency is positioning itself for a regulatory environment that relies more heavily on innovation, data, and new methods of evaluation.
The regulator said the move is about setting a long-term goal rather than announcing an immediate replacement of current systems. Even so, the decision adds momentum to efforts already under way to reduce dependence on animal testing and align regulation with newer scientific approaches.
Why it matters for medicines and regulation
For the pharmaceutical industry, the shift could influence how medicines are developed and assessed in the UK and beyond. For patients, the promise is a regulatory system that can support faster and more modern development without compromising safety. The MHRA’s statement did not set out a timetable for full replacement, but its wording suggests the agency wants to help drive a gradual transition across the sector.
The latest move also reflects the increasingly international nature of medicines regulation. By joining global regulators in the call, the MHRA is signalling that the UK wants to remain part of the conversation as authorities look for alternatives to traditional testing models.
For now, the message from the regulator is clear: replacing animal testing remains a long-term objective, but one it now wants to advance across every stage of medicine development.
Source: MHRA joins global regulators in call to advance alternatives to animal testing
Photo source: AI-generated or edited image
